JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

Search

Cytek Biosciences Inc

Suletud

SektorTervishoid

5.16 3.41

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.88

Max

5.19

Põhinäitajad

By Trading Economics

Sissetulek

105K

-5.5M

Müük

6.7M

52M

Aktsiakasum

-0

Kasumimarginaal

-10.476

Töötajad

692

EBITDA

6.4M

-4.2M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+23.4% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

26. veebr 2026

Turustatistika

By TradingEconomics

Turukapital

164M

665M

Eelmine avamishind

1.75

Eelmine sulgemishind

5.16

Uudiste sentiment

By Acuity

17%

83%

19 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Cytek Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. veebr 2026, 23:52 UTC

Omandamised, ülevõtmised, äriostud

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

2. veebr 2026, 23:52 UTC

Omandamised, ülevõtmised, äriostud

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

2. veebr 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2. veebr 2026, 23:38 UTC

Market Talk

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

2. veebr 2026, 23:28 UTC

Market Talk

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

2. veebr 2026, 23:23 UTC

Tulu

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

2. veebr 2026, 22:57 UTC

Tulu

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. veebr 2026, 22:22 UTC

Omandamised, ülevõtmised, äriostud

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

2. veebr 2026, 22:08 UTC

Market Talk

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

2. veebr 2026, 21:51 UTC

Tulu

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2. veebr 2026, 21:49 UTC

Tulu

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

2. veebr 2026, 21:39 UTC

Tulu

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. veebr 2026, 21:36 UTC

Tulu

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

2. veebr 2026, 21:34 UTC

Tulu

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. veebr 2026, 21:28 UTC

Omandamised, ülevõtmised, äriostud

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

2. veebr 2026, 21:23 UTC

Tulu

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

2. veebr 2026, 21:19 UTC

Tulu

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

2. veebr 2026, 21:17 UTC

Tulu

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

2. veebr 2026, 21:17 UTC

Tulu

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. veebr 2026, 21:10 UTC

Tulu

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. veebr 2026, 21:08 UTC

Tulu

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

2. veebr 2026, 21:07 UTC

Tulu

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

2. veebr 2026, 21:05 UTC

Tulu

Palantir Technologies 4Q Net $608.7M >PLTR

2. veebr 2026, 21:05 UTC

Tulu

Palantir Technologies 4Q Rev $1.41B >PLTR

2. veebr 2026, 21:05 UTC

Tulu

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

2. veebr 2026, 21:05 UTC

Tulu

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

2. veebr 2026, 21:05 UTC

Tulu

Palantir Technologies 4Q Adj EPS 25c >PLTR

2. veebr 2026, 21:05 UTC

Tulu

Palantir Technologies 4Q EPS 24c >PLTR

2. veebr 2026, 20:40 UTC

Market Talk

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Cytek Biosciences Inc Prognoos

Hinnasiht

By TipRanks

23.4% tõus

12 kuu keskmine prognoos

Keskmine 6.17 USD  23.4%

Kõrge 7.5 USD

Madal 5 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Cytek Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

1

Osta

2

Hoia

0

Müü

Tehniline skoor

By Trading Central

3.7 / 3.8Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

19 / 352 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Keskmine

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat